About Indegene
Indegene is a company based in Princeton (United States) founded in 1998 by Gaurav Kapoor, Rajesh Bhaskaran Nair, Manish Gupta, Anand Kiran, and Sanjay Suresh Parikh. Indegene has raised $255.15 million across 4 funding rounds from investors including The Carlyle Group, Syneos Health and Nadathur. The company has 4,490 employees as of March 31, 2024. Indegene has completed 11 acquisitions, including BioPharm Communications, CultHealth and Encima Group. Indegene operates in a competitive market with competitors including Zuellig Pharma, IntegriChain, Fishawack, Clinigen and Science Group, among others.
- Headquarter Princeton, United States
- Employees 4490 as on 31 Mar, 2024
- Founders Gaurav Kapoor, Rajesh Bhaskaran Nair, Manish Gupta, Anand Kiran, Sanjay Suresh Parikh
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Indegene Limited
-
Annual Revenue
$332.3 M (USD)9.64as on Mar 31, 2025
-
Net Profit
$47.64 M (USD)20.79as on Mar 31, 2025
-
EBITDA
$62.97 M (USD)4.53as on Mar 31, 2025
-
Total Equity Funding
$255.15 M (USD)
in 4 rounds
-
Latest Funding Round
$35.15 M (USD), Unspecified
Apr 16, 2021
-
Investors
The Carlyle Group
& 5 more
-
Employee Count
4490
as on Mar 31, 2024
-
Investments & Acquisitions
BioPharm Communications
& 10 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Indegene
Indegene is a publicly listed company on the NSE with ticker symbol INDGN in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Indegene
Unlock access to complete
Software Development Team
220 people
Leadership Team
83 people
Data Analysis and Operations Team
72 people
Senior Team
69 people
Sales and Marketing
54 people
Product Management Team
33 people
Associate Team
30 people
Lead Team
26 people
Unlock access to complete
Funding Insights of Indegene
Indegene has successfully raised a total of $255.15M across 4 strategic funding rounds. The most recent funding activity was a Unspecified round of $35.15 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Indegene
Indegene has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The Carlyle Group, Syneos Health and Nadathur.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
Brighton Park Capital is focused on growth equity investments.
|
Locked | Locked | Locked | |
|
Investments and philanthropy services offered by Nadathur Group.
|
Locked | Locked | Locked |
Investor details for Indegene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Indegene
Indegene has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include BioPharm Communications, CultHealth and Encima Group.
Investment portfolio details for Indegene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information available
|
Locked | Locked | 2010 | Locked | |
|
Omni-channel analytics solutions are provided for pharma marketing teams.
|
Locked | Locked | 2006 | Locked | |
|
Marketing services are provided to pharmaceutical and biopharma companies.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Indegene
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Indegene
Detailed financials for Indegene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Indegene Comparisons
Peer comparison for Indegene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Indegene
Indegene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zuellig Pharma, IntegriChain, Fishawack, Clinigen and Science Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Healthcare access in Asia is enhanced by Zuellig Pharma.
|
|
| Locked | Locked | Locked |
Inventory, order and customer relationship management solution for life science suppliers.
|
|
| Locked | Locked | Locked |
Fully integrated cross-border services are delivered to global pharmaceutical organizations.
|
|
| Locked | Locked | Locked |
Specialty medicines are supplied via clinical trials and access programs.
|
|
| Locked | Locked | Locked |
Technology-based consultancy and product development services are provided.
|
Detailed competitors of Indegene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indegene
Complete news archive for Indegene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indegene
Indegene was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Indegene is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Manish Gupta is the current CEO of Indegene. They have also founded this company.
Indegene is a funded company, having raised a total of $255.15M across 4 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Indegene is 4,490.
Annual revenue of Indegene is $332.3M as on Mar 31, 2025.
Indegene was founded in 1998 and is headquartered in Princeton, United States. Operations focus on the healthcare sector, where suite solutions are delivered to payers and providers. Payer offerings include transformation, care management, member acquisition and engagement, healthcare analytics, and Medicare analysis. ACO solutions encompass transformation services, outcomes improvement, patient engagement, and analytics. Cloud-based platforms are operated for customer engagement, member loyalty and retention, and care management.
Indegene's top competitors include Zuellig Pharma, IntegriChain and Clinigen.
Yes, Indegene is publicly traded on NSE under the ticker symbol INDGN.
Indegene has made 11 acquisitions, including BioPharm Communications, CultHealth, and Encima Group.
Indegene has 6 investors. Key investors include The Carlyle Group, Syneos Health, Nadathur, Karnataka Information Technology Venture Capital Fund, and Brighton Park Capital.
The ticker symbol of Indegene is INDGN on NSE.
The valuation of Indegene is $598.56M as of Apr 2021.